

**Cancer Programs Practice Profile Reports (CP³R), version 3
 Rapid Quality Reporting System (RQRS)**

The following updates to the measure specifications were applied on August 06, 2019		
Change	Measures affected	Description
Colon and Breast updates	ACT	Updated the order of processing edits in the rules to issue the NE messages (if applicable) first, and issue the incomplete TNM edits last.
	12RLN	
	BCSRT	
	MAC	
	HT	
	MASTRT	
		Result: This will eliminate the confusion of getting an incomplete TNM message when the case was NE for some other reason.
Other Breast rule updates	MAC	1) Use Most Definitive Surgery Date rather than First Surgery date to identify cases with neo-adjuvant treatment.
	HT	2) The “Unknown tumor size” message will be changed to “check pN” when pN is blank and Tumor Size is entered.
	Result: 1) Neo-adjuvant treatment will be determined by the Most Definitive Surgery date. Some cases that did not have neo-adjuvant treatment based on First Surgery date can now be defined as having neo-adjuvant treatment based on the Most Definitive Surgery date. 2) The “check pN” message will display when pN is blank and Tumor Size is entered.	

June 30, 2019		
Change	Measures affected	Description
Colon and Breast AJCC8/NAACCRv18 updates	ACT	AJCC8/NAACCRv18 updates for dx year ≥2018: update histology codes, cM, pM, cStage, pStage Group codes, Site-Specific Data Items (SSDI), and Radiation Codes
	12RLN	
	BCSRT	
	MAC	
	HT	
	MASTRT	
		Result: RQRS will accept cases in the NAACCRv18 format. The RQRS Breast and Colon Quality Measures will perform AJCC8 staging on 2018 cases and will use the new SSDI codes when needed. Cases diagnosed before 2018 will continue to be staged by AJCC7 and will continue to use the existing Collaborative Stage Site-Specific Factors where needed. The use of new v18 Radiation fields and codes will be allowed for all cases. CP3R will start processing dx 2018 cases in 2020, so the remaining CP3R measures will be updated then.

Other Breast rule updates	MAC	1. Add unknown chemo therapy (01) with BRM as compliant if HER2 positive. 2. Rule name update: "Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer"
	Result: HER2 positive cases with chemotherapy 01 and BRM recommended or administered within 120 days of dx will be compliant with this measure.	
	MAC	1. For all dx years, include cases with neo-adjuvant treatment regardless of tumor size
	HT	2. For cases dx 2018 and later, use AJCC8 SSDI codes: ER/PR% for HR selection
Result: Beginning with the AJCC8, pathologic TNM staging is no longer recorded for cases undergoing neo-adjuvant treatment. In the existing rules these cases would have been marked as incomplete. MAC and HT measures will be changed as follows: MAC: if a patient received neo-adjuvant treatment and they are ER/PR- they would be compliant independent of tumor size if they receive combination chemo therapy within 120 days of dx. HT: if a patient received neo-adjuvant treatment and they are ER/PR+ they would be compliant independent of tumor size if they receive hormone therapy within 365 days of dx.		
Breast doc only clarifications	BCS	Doc only clarification to Exclusion 90.
	Result: No rule change. Cases for patients who refused BCS lumpectomy but chose mastectomy instead, can be manually excluded from this measure with Exclusion 90.	
	nBx	Doc only clarification: The definition for excluding unknown Surgical Diagnostic and Staging Procedure 07, 09 has been moved to the Eligibility criteria.
	Result: No rule change. Unknown diagnostic or staging procedure is non-eligible.	

November 15, 2018

Change	Measures affected	Description
Updates to CP3R bladder measures	BL2RLN	The Charlson Deyo score automatic calculation has been updated to use either the ICD-9 Comorbidities and Complications (1-10) or ICD-10 Secondary Diagnosis (1-10) if available. CP3R will display the new ICD-10 Secondary Diagnosis (1-10) codes and the new recalculated Charlson Deyo score.
	BLCT	
	BLCSTRI	
	Result: If ICD-10 Secondary Diagnosis are entered in the case, the recalculated Charlson Deyo score will reflect the ICD-10 Secondary Diagnosis (1-10). If ICD-10 codes are not entered, Charlson Deyo score will reflect the ICD-9 Comorbidities and Complications (1-10).	

June 2017

Change	Measures affected	Description
New CP3R bladder measure	BLCT	Neo-adjuvant or adjuvant chemotherapy offered or administered for patients with muscle invasive cancer undergoing radical cystectomy
	Result: New surveillance measure	
New CP3R bladder measure	BLCSTRI	Radical or partial cystectomy; or Tri-modality therapy (Local tumor destruction/excision with chemotherapy and radiation) for clinical T234N0M0 patients, first treatment within 90 days of diagnosis
	Result: New surveillance measure.	
New CP3R kidney	PD1RLN	Pediatric Kidney Measure: At least 1 regional lymph node is removed and pathologically examined for primarily resected unilateral nephroblastoma

measure	Result: New Quality Improvement measure.	
Addition of censor (RQRS & CP3R)	12RLN	Addition of censor 43 to this Colon measure for: <ul style="list-style-type: none"> Positive FNA, nodes from surgery negative due to neo-adjuvant chemo
	Result: This censor will allow registrars to move patients in which: Regional lymph node(s) were positive on FNA (95), but lymph nodes from surgery were negative because of neo-adjuvant chemotherapy currently labeled as Incomplete to Not Eligible	

August 2016		
Change	Measures affected	Description
Addition of p- and c- prefixes to AJCC TNM staging elements	All	All AJCC T, N, and M data elements in the measure business rules and in the RQRS and CP ³ R applications have been updated to display the c- and p- prefixes for NAACCR v16 compliance. Previously submitted data has been converted to add these prefixes.
	Result: This has no effect on the measure calculations. All measure rules have been updated to account for the NAACCR v16 data format and previously submitted data has been converted.	
Tumor size	Breast MAC & HT	For cases diagnosed in 2016 and later use the data item Tumor Size Summary (NAACCR Item #756) instead of the discontinued data item CS Tumor Size (NAACCR Item # 2800)
	Result: This has no effect on the measure calculation.	
Addition of censor	Melanoma of the skin: MCLND	Addition of censors to this measure for: <ul style="list-style-type: none"> Patient enrolled in a clinical trial that directly impacts delivery of the standard of care (80) Patient refusal (90)
	Result: This has no effect on the current measure calculation. However, programs will now be able to excluded patients from this measure.	

April 2016		
Change	Measures affected	Description
New Melanoma and Bladder measures reported in CP³R	M10AxLN, M05IgLN, MCLND, BL2RLN	The following surveillance measures are now included in CP ³ R: <p><i>Melanoma</i></p> <ul style="list-style-type: none"> At least 10 regional lymph nodes are removed and examined in Axillary lymph node dissection (M10AxLN) At least 5 regional lymph nodes are removed and examined in Inguinal lymph node dissection (M05IgLN) Completion Lymph Node Dissection use after positive Sentinel Lymph Nodes biopsy (MCLND) <p><i>Bladder:</i></p> <ul style="list-style-type: none"> At least 2 lymph nodes are removed in patients undergoing partial or radical cystectomy (BL2RLN)
	Result: EPRs will be reported for cases diagnosed from 2010 – 2013 for these measures. These measures are not assessed during CoC Surveys.	
Unknown stage designated	All	Cases with unknown stage will now be designated as ‘Incomplete’ instead of ‘Not Eligible’.
	Result: Potential increase in the number of cases labeled as incomplete in need of additional review.	
Ovarian OVSAL	OVSAL	AJCC TNM Path T of 1B has been added as a valid code.

stage	Result: Potential slight change in EPRs based on increased number of cases eligible for this measure.	
New measure added to RQRS	MASTRT	The following accountability measure is now reported in RQRS: •Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. (MASTRT)
	Result: Programs will be able to assess this measure in real clinical time.	
Manual case exclusions allowed in RQRS	All reported measures	Manual case exclusions will now be allowed in RQRS. Measure exclusions will be added to the RQRS case list and updated nightly.
	Result: Programs will be able to utilize the manual case exclusions in RQRS, the case status will update overnight.	
Measure abbreviation	BCSRT	The abbreviation of the RQRS “BCS” measure ‘Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer’ has been updated to “BCSRT” to be more consistent with CP ³ R
	Result: Consistency between RQRS and CP ³ R for measure abbreviations.	

December 2015		
Change	Measures affected	Description
Include 4 years of data	All	Estimated Performance Rates will be reported for four diagnosis years.
	Result: EPRs will be reported for cases diagnosed from 2010 – 2013. 2010 data will be displayed in CP ³ R until summer 2016 with the next release of data. EPRs have not previously been displayed for some gynecologic measures. Programs are not expected to review these retrospective cases.	
Needle biopsy	nBx	Title updated to; ‘Image or palpation guided biopsy to the primary site is used to establish diagnosis of breast cancer’
	Result: No change to measure specifications, this change is to better capture the intent and application of this quality measure.	
	nBx	Updates to the measure exclusions have been added for the needle biopsy measure. Changes include: <ul style="list-style-type: none"> • Patient presents with co-morbid conditions that directly impacts delivery of the standard of care (updated definition) • Diagnosed via cytology FNA (new exclusion)
Update of CoC Standard Ratings	All measures assessed by Standards 4.4 & 4.5	CoC Standards and expected EPRs are updated to the expected EPRs for 2013 diagnoses in 2016 surveys, which start in January.
	Result: Measures and rates designated in this column refers to 2013 expected EPRs surveyed during 2016.	

November 2015		
Change	Measures affected	Description
Measure Histologies updates	CERCT, ENDCTRT, ENDLRC, and OVSAL	Measures will now include only epithelial histologies for all cases, regardless of AJCC or FIGO staging
	Result: On average, programs should see a minor decrease in denominator-eligible cases with a slight increase in EPR	

New Measure Exclusions	BCSRT, HT, MAC, BCS, MASTRT, ACT, RECRTCT, LCT, LNoSurg, CBRRT, CERRT, , CERCT, ENDCTRT, ENDLRC, OVSAL	Addition of measure exclusion for: 'Patient enrolled in a clinical trial that directly impacts delivery of the standard of care'.
	Result: Programs will be able to exclude cases from specific measures if participation in a clinical trial impacted the delivery of care assessed by the measure.	
	nBx	Additional measure exclusions have been added to the needle biopsy measure. The complete measure exclusions are: <ul style="list-style-type: none"> • Patient refusal • Patient medically unable to hold position for image guided biopsy • Patient requires sub areolar excision for nipple discharge • Lesion too superficial • Breast too small • Lesion inaccessible by needle biopsy • Cancer found in prophylactic mastectomy or through an elective procedure • Benign, high risk lesions diagnosed by needle biopsy, requiring excisional biopsy • Discordant biopsy results compared to suspicious imaging • Patient presents with co-morbid conditions
	Result: Programs will have additional control to be able to exclude cases which did not receive needle biopsy prior to breast cancer diagnosis.	
	12RLN	Measure exclusions were added for the 12RLN measure: <ul style="list-style-type: none"> • Perforation of the primary site • Acute obstruction
Result: Programs will have the ability to exclude cases from the 12RLN measure for these specific reasons.		

Breast Conserving Surgery Staging	BCS	Allow blank clinical T, pathologic in situ , clinical N0, clinical M0, with Clinical Stage Group 0
	Result: Clinical stage 0 cases coded with blank clinical T which were previously coded as incomplete may become eligible for the BCS measure.	
Vital Status required for CERRT	CERRT	Add Vital status check to cervix CERRT measure
	Result: Cases which are currently labeled as Incomplete will become Not Eligible for the measure. There is no EPR change	
Replace considered with recommended	MAC, HT, MASTRT, ACT, RECRTCT, LCT	Measures with the description of therapy 'considered or administered' will now read 'recommended or administered'.
	Effect: None. This change has been made to harmonize the measure title with the coding descriptions in FORDS. Example: Combination chemotherapy is <i>considered</i> or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer. Is now: Combination chemotherapy is <i>recommended</i> or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer.	
Ovarian chemotherapy measure	OVCT	Chemotherapy started within 42 days (before or after) the Date of Most Definite Surgery in Stages IA-IV Ovarian, Fallopian Tube, or Peritoneal cancers (OVCT) will be removed from CP3R.

removed	Effect: Programs will not see this measure in their CP3R rates. The NCDB is completing a review of this measure and its specifications with the measure developer and will re-release when it is complete.
----------------	---

For further technical assistance, please contact NCDB Staff at NCDB@facs.org